tbuckley/cabot-search huggingface dataset:
Molecular mechanisms of inhibiting glucosyltransferases for biofilm formation in Streptococcus mutans
Authors: Qiong Zhang, Qizhao Ma, Yan Wang, Hui Wu, Jing Zou
Journal: International Journal of Oral Science (2021)

Glucosyltransferases (Gtfs) play critical roles in the etiology and pathogenesis of Streptococcus mutans (S. mutans)- mediated dental caries including early childhood caries. Gtfs enhance the biofilm formation and promotes colonization of cariogenic bacteria by generating biofilm extracellular polysaccharides (EPSs), the key virulence property in the cariogenic process. Therefore, Gtfs have become an appealing target for effective therapeutic interventions that inhibit cariogenic biofilms. Importantly, targeting Gtfs selectively impairs the S. mutans virulence without affecting S. mutans existence or the existence of other species in the oral cavity. Over the past decade, numerous Gtfs inhibitory molecules have been identified, mainly including natural and synthetic compounds and their derivatives, antibodies, and metal ions. These therapeutic agents exert their inhibitory role in inhibiting the expression gtf genes and the activities and secretion of Gtfs enzymes with a wide range of sensitivity and effectiveness. Understanding molecular mechanisms of inhibiting Gtfs will contribute to instructing drug combination strategies, which is more effective for inhibiting Gtfs than one drug or class of drugs. This review highlights our current understanding of Gtfs activities and their potential utility, and discusses challenges and opportunities for future exploration of Gtfs as a therapeutic target.
137P Trial comparing the safety, efficacy and immunogenicity of trastuzumab biosimilar candidate (TX05) with originator trastuzumab in HER2+ early breast cancer
Authors: P. Krivorotko, A. Manikhas, F. Moiseenko, E. Poddubskaya, S.P. Neciosup, M. Gopichand, D. Osynskyi, T. Haynes, J. Lai, B.J. Mills
Journal: Annals of Oncology (2021)
Erratum: “Rare, protein-altering variants in <i>AS3MT</i> and arsenic metabolism efficiency: a multi-population association study”
Authors: Dayana A. Delgado, Meytal Chernoff, Lei Huang, Lin Tong, Lin Chen, Farzana Jasmine, Justin Shinkle, Shelley A. Cole, Karin Haack, Jack Kent, Jason Umans, Lyle G. Best, Heather Nelson, Donald Vander Griend, Joseph Graziano, Muhammad G. Kibriya, Ana Navas-Acien, Margaret R. Karagas, Habibul Ahsan, Brandon L. Pierce
Journal: Environmental Health Perspectives (2021)
1354P Comparison of different hyperprogressive disease criteria in non-small cell lung cancer patients treated with immunotherapy and correlation with somatic mutations in driver genes
Authors: M. Zuazo, H. Arasanz, L. Chocarro, A.I. Bocanegra Gondan, M. Martínez-Aguillo, I. Morilla Ruiz, L. Teijeira, D. Guerrero, L.M. Nova, T. Zudaire, M. Arriola, A. Patiño-Garcia, R. Pío, G. Kochan, D. Escors, R. Vera
Journal: Annals of Oncology (2021)
Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer
Authors: Henan Zhang, Jacob J. Orme, Feven Abraha, B.J. Stish, Val J. Lowe, Fabrice Lucien, Erik J. Tryggestad, Michael S. Bold, Lance C. Pagliaro, C. Richard Choo, Debra H. Brinkmann, Matthew J. Iott, Brian J. Davis, J. Fernando Quevedo, William S. Harmsen, Brian A. Costello, Geoffrey B. Johnson, Mark A. Nathan, Kenneth R. Olivier, Thomas M. Pisansky, Eugene D. Kwon, Haidong Dong, Sean S. Park
Journal: Clinical Cancer Research (2021)

Outcomes for resistant metastatic castration-resistant prostate cancer (CRPC) are poor. Stereotactic ablative radiotherapy (SABR) induces antitumor immunity in clinical and preclinical studies, but immunologic biomarkers are lacking.Eighty-nine patients with oligometastatic CRPC were identified by 11C-Choline-PET (Choline-PET) from August 2016 to December 2019 and treated with SABR. Prespecified coprimary endpoints were 2-year overall survival (OS) and PSA progression. Secondary endpoints included 2-year SABR-treated local failure and 6-month adverse events. Correlative studies included peripheral blood T-cell subpopulations before and after SABR.128 lesions in 89 patients were included in this analysis. Median OS was 29.3 months, and 1- and 2-year OS were 96% and 80%, respectively. PSA PFS was 40% at 1 year and 21% at 2 years. Local PFS was 84.4% and 75.3% at 1 and 2 years, respectively, and no grade ≥3 AEs were observed. Baseline high levels of tumor-reactive T cells (TTR; CD8+CD11ahigh) predicted superior local, PSA, and distant PFS. Baseline high levels of effector memory T cells (TEM; CCR7-CD45RA-) were associated with improved PSA PFS. An increase in TTR at day 14 from baseline was associated with superior OS.This is the first comprehensive effector T-cell immunophenotype analysis in a phase II trial before and after SABR in CRPC. Results are favorable and support the incorporation of immune-based markers in the design of future randomized trials in patients with oligometastatic CRPC treated with SABR.
945P Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE): Updated results from a multi-center prospective cohort study
Authors: J. Chen, L. Lu, T-F. Wen, C-D. Lu, Y-Y. Zeng, B-D. Xiang, X. Xu, Z-Y. Huang, X-C. Li, T. Zhang, L-X. Qin
Journal: Annals of Oncology (2021)
Early targeted heart rate aerobic exercise versus placebo stretching for sport-related concussion in adolescents: a randomised controlled trial
Authors: John J Leddy, Christina L Master, Rebekah Mannix, Douglas J Wiebe, Matthew F Grady, William P Meehan, Eileen P Storey, Brian T Vernau, Naomi J Brown, Danielle Hunt, Fairuz Mohammed, Andrea Mallon, Kate Rownd, Kristy B Arbogast, Adam Cunningham, Mohammad N Haider, Andrew R Mayer, Barry S Willer
Journal: The Lancet Child & Adolescent Health (2021)
1136P A clinically applicable cervical cancer artificial intelligence screening system for accurate cytopathological diagnosis: A multicenter population-based study and randomized controlled trial
Authors: Y. Yu, J. Wang, Y. Tan, H. Wan, N. Zheng, Z. He, L. Mao, W. Ren, Z. Lin, G. He, Y. Chen, J. Wang, N. Ouyang, H. Yao
Journal: Annals of Oncology (2021)
Abstract 14981: Healthcare Access to TAVR Procedures by Population Density: A Focus on Healthcare Disparity in Florida
Authors: Abdulla A Damluji, Richard Epstein, Mauro Moscucci, Stefan Rayer, Ying Wang, Mauricio G Cohen, Jon R Resar, David J Cohen, Christopher O’Connor, Wayne B Batchelor, Michael Fabbro
Journal: Circulation (2019)

Introduction: We aimed to compare healthcare disparity based on access to TAVR centers in Florida using travel time and distance according to population density per square mile. Methods: We used da...
METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events
Authors: Fanpeng Zhao, Ying Xu, Shichao Gao, Lixia Qin, Quillan Austria, Sandra L. Siedlak, Kinga Pajdzik, Qing Dai, Chuan He, Wenzhang Wang, James M. O’Donnell, Beisha Tang, Xiongwei Zhu
Journal: Molecular Neurodegeneration (2021)

N6-methyladenosine (m6A) modification of RNA influences fundamental aspects of RNA metabolism and m6A dysregulation is implicated in various human diseases. In this study, we explored the potential role of RNA m6A modification in the pathogenesis of Alzheimer disease (AD).We investigated the m6A modification and the expression of m6A regulators in the brain tissues of AD patients and determined the impact and underlying mechanism of manipulated expression of m6A levels on AD-related deficits both in vitro and in vivo.We found decreased neuronal m6A levels along with significantly reduced expression of m6A methyltransferase like 3 (METTL3) in AD brains. Interestingly, reduced neuronal m6A modification in the hippocampus caused by METTL3 knockdown led to significant memory deficits, accompanied by extensive synaptic loss and neuronal death along with multiple AD-related cellular alterations including oxidative stress and aberrant cell cycle events in vivo. Inhibition of oxidative stress or cell cycle alleviated shMettl3-induced apoptotic activation and neuronal damage in primary neurons. Restored m6A modification by inhibiting its demethylation in vitro rescued abnormal cell cycle events, neuronal deficits and death induced by METTL3 knockdown. Soluble Aβ oligomers caused reduced METTL3 expression and METTL3 knockdown exacerbated while METTL3 overexpression rescued Aβ-induced synaptic PSD95 loss in vitro. Importantly, METTL3 overexpression rescued Aβ-induced synaptic damage and cognitive impairment in vivo.Collectively, these data suggested that METTL3 reduction-mediated m6A dysregulation likely contributes to neurodegeneration in AD which may be a therapeutic target for AD.
CN1 Remote monitoring by Nurses Navigators (NNs): From experimentation to optimisation of routine practices
Authors: A. Duflot Boukobza, M. Ferrua, D. Mathivon, M. Abbas, J. Legendre, V. Puglisi, A. Fourcade, F. Pommeret, F. Scotté, M. di Palma, E. Minvielle, O. Mir
Journal: Annals of Oncology (2021)
1113P Care for neuroendocrine tumor patients, monitored by medical oncologists: Comparative data Europe vs North America
Authors: T. Kolarova, M. McDonnell, C.V. Bouvier, M.E. Pavel, H. Singh, J. Howe, S. Singh, D. O'Toole, J. Chen, S. Leyden, E. Gellerman, S. Dureja, C. Rodien-Louw, D. Van Genechten
Journal: Annals of Oncology (2021)
910P Repurposing pantoprazole in advanced head and neck squamous cell carcinoma: A phase I/II randomized study
Authors: V. Noronha, V.M. Patil, D. Kalra, N.S. Menon, K. Nawale, V. Mathrudev, M.Y. Singh, A. Singh, S. Adak, M. Sandesh, R. Arunkumar, S. Kumar, A. Mahajan, K. Prabhash
Journal: Annals of Oncology (2021)
The Oregon Health Plan — Lessons for the Nation
Authors: T Bodenheimer
Journal: New England Journal of Medicine (1997)

Expansion PlansUnder Oregon's 1989 legislative package, the Medicaid portion of the Oregon Health Plan was only one of its two critical pieces. The other was the requirement that employers provide insurance to employees, with the prioritized list as the minimal benefit package. Small businesses lobbied for the repeal of this part of the legislation, and on January 1, 1996, it died. Gone was the hope of nearly universal health insurance in Oregon, with the prioritized list used for persons with incomes above the federal poverty level as well as Medicaid beneficiaries.With the defeat of the requirement that employers . . .
A case of COVID-19 vaccination-associated forme fruste purpura fulminans
Authors: J. Griss, S. Eichinger, S. Winkler, W. Weninger, P. Petzelbauer
Journal: British Journal of Dermatology (2021)

Abstract We report the case of a female, 77 year old patient with multi-localized skin infarctions following vaccination with mRNA-1273 (Moderna). This phenomenon is to our knowledge otherwise only seen in infection-associated purpura fulminans - which was thoroughly ruled out in our patient. This report demonstrates that we need to be vigilant of a wider array of vascular phenomena related to Covid vaccinations.
1088P Adjuvant dabrafenib plus trametinib (DT) treatment completion in patients with resected melanoma in Spain: A retrospective observational study (GEM 1901 - DESCRIBE-AD)
Authors: J.L. Manzano, J. Martín-Liberal, L.A. Fernandez-Morales, G. Benítez, J. Medina, M. Quindós, A. García-Castaño, O. Fernández, R. Vilchez Simo, M. Majem, L. Bellido Hernández, P. Ayala de Miguel, B. Campos, E. Espinosa, J.A. Macías Cerrolaza, I. Gil-Arnaiz, D. Lorente, A. Martínez-Fernández, E. Martín-Sánchez, P. Cerezuela-Fuentes
Journal: Annals of Oncology (2021)
311P A global survey of the management of carcinomatous meningitis (CM) in breast cancer patients
Authors: E. Razis, A.G. Thulin, R. Bartsch, M.J. Escudero, B. Linderholm, D. Fumagali, G. Rossi, M. Gill Gill, V. Müller, C. Palmieri, N. Kotecki, I. Witzel
Journal: Annals of Oncology (2021)
749P Cardiotoxicity in patients treated with PARP-inhibitors
Authors: M. Blanco Clemente, M. Martinez Cutillas, Y. Garitaonaindía Díaz, C.D. Mitroi, B. Núñez García, M. Mendez, J.C. Sánchez González, B. Cantos Sánchez de Ibargüen, A. Gonzalez del Alba, B. Menchen Viso, M. Provencio Pulla, C. Maximiano Alonso
Journal: Annals of Oncology (2021)
Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses
Authors: Ryo Shinnakasu, Shuhei Sakakibara, Hiromi Yamamoto, Po-hung Wang, Saya Moriyama, Nicolas Sax, Chikako Ono, Atsushi Yamanaka, Yu Adachi, Taishi Onodera, Takashi Sato, Masaharu Shinkai, Ryosuke Suzuki, Yoshiharu Matsuura, Noritaka Hashii, Yoshimasa Takahashi, Takeshi Inoue, Kazuo Yamashita, Tomohiro Kurosaki
Journal: The Journal of Experimental Medicine (2021)

Broadly protective vaccines against SARS-related coronaviruses that may cause future outbreaks are urgently needed. The SARS-CoV-2 spike receptor-binding domain (RBD) comprises two regions, the core-RBD and the receptor-binding motif (RBM); the former is structurally conserved between SARS-CoV-2 and SARS-CoV. Here, in order to elicit humoral responses to the more conserved core-RBD, we introduced N-linked glycans onto RBM surfaces of the SARS-CoV-2 RBD and used them as immunogens in a mouse model. We found that glycan addition elicited higher proportions of the core-RBD-specific germinal center (GC) B cells and antibody responses, thereby manifesting significant neutralizing activity for SARS-CoV, SARS-CoV-2, and the bat WIV1-CoV. These results have implications for the design of SARS-like virus vaccines.
An observational study of Internet behaviours for adolescent females following sexual abuse
Authors: Jennie G. Noll, Ann-Christin Haag, Chad E. Shenk, Michelle F. Wright, Jaclyn E. Barnes, Mojtaba Kohram, Matteo Malgaroli, David J. Foley, Michal Kouril, George A. Bonanno
Journal: Nature Human Behaviour (2021)
The evolutionary benefit of less-credible affective musical signals for emotion induction during storytelling
Authors: Caitlyn Trevor, Sascha Frühholz
Journal: Behavioral and Brain Sciences (2021)

Abstract The credible signaling theory underexplains the evolutionary added value of less-credible affective musical signals compared to vocal signals. The theory might be extended to account for the motivation for, and consequences of, culturally decontextualizing a biologically contextualized signal. Musical signals are twofold, communicating “emotional fiction” alongside biological meaning, and could have filled an adaptive need for affect induction during storytelling.
LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)
Authors: N.S. Vasudev, G. Ainsworth, S. Brown, L. Pickering, T.S. Waddell, K. Fife, R. Griffiths, A. Sharma, E. Katona, H. Howard, G. Velikova, A. Maraveyas, J.E. Brown, B. Venugopal, P. Patel, A. Jain, S. Symeonides, P.D. Nathan, F. Collinson, T.B. Powles
Journal: Annals of Oncology (2021)
745P Ovarian Cancer Retrospective European (O’CaRE) observational study to assess burden of disease and time to next treatment in real-world clinical practice: Results from the United Kingdom (UK)
Authors: J. McGrane, D. Shaw, A. Anand, T.K. Madhuri, J. Krell, L. Saunders, C. Hawkes, J.M. Schilder, W. York, J. Astrom
Journal: Annals of Oncology (2021)
128P Characteristics, patterns of care and outcomes of young women with breast cancer (BC) according to age, year of diagnosis and germline BRCA status (gBRCA)
Authors: K. Punie, M.A. Franzoi, B. Dullens, A. Laenen, C. Fernandes Costa, H. Wildiers, P. Neven, E. de Azambuja, M. Lambertini
Journal: Annals of Oncology (2021)
686P Angiogenesis related blood biomarkers of response to checkpoint inhibitors (IO) and VEGFR-TKI in metastatic renal cell carcinoma (mRCC): Results from the BIONIKK prospective trial
Authors: L. Mauge, I. Galy-Fauroux, R-T. Elaidi, L. Ben Dhia, S. Bertil, M. Bennamoun, C.M. Chevreau, D. Borchiellini, D. Pannier, D. Maillet, M. Gross-Goupil, C. Tournigand, B. Laguerre, P. Barthelemy, F. Joly, G. Gravis, J. Zucman-Rossi, S.M. Oudard, Y. Vano, D. Helley
Journal: Annals of Oncology (2021)
1071P A nationwide, real-life study of outcome and quality of life after the introduction of adjuvant immunotherapy for Danish melanoma patients
Authors: E. Ellebaek, R.B. Holmstrøm, C.H. Ruhlmann, H. Schmidt, C.A. Haslund, M. Donia, A. von Heymann, C. Johansen, L. Bastholt, I.M. Svane
Journal: Annals of Oncology (2021)
Signaling games and music as a credible signal
Authors: Massimo Lumaca, Elvira Brattico, Giosuè Baggio
Journal: Behavioral and Brain Sciences (2021)

Abstract The argument by Mehr et al. that music emerged and evolved culturally as a credible signal is convincing, but it lacks one essential ingredient: a model of signaling behavior that supports the main hypothesis theoretically and empirically. We argue that signaling games can help us explain how musical structures emerge as population-level phenomena, through sender–receiver signaling interactions.
Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans
Authors: Yinong Young-Xu, Caroline Korves, Jeff Roberts, Ethan I. Powell, Gabrielle M. Zwain, Jeremy Smith, Hector S. Izurieta
Journal: JAMA Network Open (2021)

Effectiveness of mRNA vaccinations in a diverse older population with high comorbidity is unknown.To describe the scope of the COVID-19 vaccination rollout among US veterans, and to estimate mRNA COVID-19 vaccine effectiveness (VE) as measured by rates of SARS-CoV-2 infection.This matched test-negative case-control study was conducted using SARS-CoV-2 test results at Veterans Health Administration sites from December 14, 2020, to March 14, 2021. Vaccine coverage was estimated for all veterans. VE against SARS-CoV-2 infection and COVID-19-related hospitalization and death were estimated using electronic health records from veterans who routinely sought care at a VHA facility and had a test result positive for SARS-CoV-2 (cases) or negative for SARS-CoV-2 (controls). Cases and controls were matched on time of test and geographic region. Data were analyzed from May to July 2021.Vaccination status, defined as unvaccinated, partially vaccinated (≥14 days after first dose until second dose), or fully vaccinated (≥14 days after second dose), at time of test.The main outcome of interest was a positive result for SARS-CoV-2 on a polymerase chain reaction or antigen test. Secondary outcomes included COVID-19-related hospitalization and death, defined by discharge data and proximity of event to positive test result. VE was estimated from odds ratios for SARS-CoV-2 infection with 95% CIs.Among 6 647 733 veterans included (3 350 373 veterans [50%] aged ≥65 years; 6 014 798 [90%] men and 632 935 [10%] women; 461 645 Hispanic veterans of any race [7%], 1 102 471 non-Hispanic Black veterans [17%], and 4 361 621 non-Hispanic White veterans [66%]), 1 363 180 (21%) received at least 1 COVID-19 vaccination by March 7, 2021. In this period, during which the share of SARS-CoV-2 variants Alpha, Epsilon, and Iota had started to increase in the US, estimates of COVID-19 VE against infection, regardless of symptoms, was 95% (95% CI, 93%-96%) for full vaccination and 64% (95% CI, 59%-68%) for partial vaccination. Estimated VE against COVID-19-related hospitalization for full vaccination was 91% (95% CI 83%-95%); there were no deaths among veterans who were fully vaccinated. VE against infection was similar across subpopulations (non-Hispanic Black, 94% [95% CI, 88%-97%]; Hispanic [any race], 83% [95% CI, 45%-95%]; non-Hispanic White, 92% [95% CI 88%-94%]; rural, 94% [95% CI, 89%-96%]; urban, 93% 95% CI, 89%-95%]).For veterans of all racial and ethnic subgroups living in urban or rural areas, mRNA vaccination was associated with substantially decreased risk of COVID-19 infection and hospitalization, with no deaths among fully vaccinated veterans.
731P Multi-maintenance olaparib in relapsed, platinum-sensitive BRCA-mutant high-grade serous ovarian carcinoma (MOLTO): A phase II feasibility study
Authors: R.D. Morgan, A.R. Clamp, W.D.J. Ryder, C. Wheeler, E. Buckley, J. Truelove, A.D. Murphy, J. Hasan, C.L. Mitchell, G.J. Burghel, D. White, M. Price, S.S. Bhaskar, J. Shaw, C. Dive, A.J. Wallace, J.P. O'Connor, D. Rothwell, R.J. Edmondson, G.C. Jayson
Journal: Annals of Oncology (2021)
616P Real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis
Authors: D.J. George, N. Agarwal, K. Ramaswamy, R. Sandin, D. Russell, A. Hong, H. Yang, W. Gao, K. Hagan, S.J. Freedland
Journal: Annals of Oncology (2021)
1261P Trastuzumab/pertuzumab combination therapy in advanced pre-treated HER2-mutated non-small cell lung cancer: Results of a DRUP trial cohort
Authors: J. van Berge Henegouwen, M. Jebbink, L. Hoes, H. van der Wijngaart, L. Zeverijn, D. van der Velden, P. Roepman, W. de Leng, A. Jansen, E. van Werkhoven, V. van der Noort, A.J. van der Wekken, S. Burgers, E.F. Smit, H. Verheul, E. Voest, H. Gelderblom
Journal: Annals of Oncology (2021)
1811P Molecular characterization of epidermal growth factor receptor-mutated (EGFR-m) non-small cell lung cancer (NSCLC) undergoing histological transformation
Authors: L. Bonanno, M.L. Reale, A. Ferro, L. Righi, S. Indraccolo, A. Listì, E. Zulato, G. Nardo, C. Bennati, G. Rossi, F. Verderame, F. Guddo, G. Pasello, P. Bironzo, F. Calabrese, V. Guarneri, P. Conte, S. Novello
Journal: Annals of Oncology (2021)
Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy
Authors: Marie Tourret, Nana Talvard-Balland, Marion Lambert, Ghada Ben Youssef, Mathieu F Chevalier, Armelle Bohineust, Thomas Yvorra, Florence Morin, Saba Azarnoush, Olivier Lantz, Jean-Hugues Dalle, Sophie Caillat-Zucman
Journal: Journal for ImmunoTherapy of Cancer (2021)

Mucosal-associated invariant T (MAIT) cells are semi-invariant T cells that recognize microbial antigens presented by the highly conserved MR1 molecule. MAIT cells are predominantly localized in the liver and barrier tissues and are potent effectors of antimicrobial defense. MAIT cells are very few at birth and accumulate gradually over a period of about 6 years during the infancy. The cytotoxic potential of MAIT cells, as well as their newly described regulatory and tissue repair functions, open the possibility of exploiting their properties in adoptive therapy. A prerequisite for their use as 'universal' cells would be a lack of alloreactive potential, which remains to be demonstrated. We used ex vivo, in vitro and in vivo models to determine if human MAIT cells contribute to allogeneic responses. We show that recovery of MAIT cells after allogeneic hematopoietic stem cell transplantation recapitulates their slow physiological expansion in early childhood, independent of recovery of non-MAIT T cells. In vitro, signals provided by allogeneic cells and cytokines do not induce sustained MAIT cell proliferation. In vivo, human MAIT cells do not expand nor accumulate in tissues in a model of T-cell-mediated xenogeneic graft-versus-host disease in immunodeficient mice. Altogether, these results provide evidence that MAIT cells are devoid of alloreactive potential and pave the way for harnessing their translational potential in universal adoptive therapy overcoming barriers of HLA disparity. ClinicalTrials.gov number NCT02403089.